Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441514 | 0.84 | SLC2A1 (0.43) | KDM4EDAOKMT2A | |
| SCHEMBL439165 | 0.75 | NPSR1 (0.38) | ALDH1A1KDM4EHSD17B10SMN1; SMN2POLB | |
| SCHEMBL1346299 | 0.74 | IDH1 (0.49) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL439327 | 0.72 | SMN1; SMN2 (0.38) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14067135 | 0.72 | POLB (0.52) | ALDH1A1KDM4ECYP3A4HSD17B10SMN1; SMN2 | |
| SCHEMBL20828256 | 0.71 | TYMP (0.65) | ALDH1A1KDM4ETYMPHSD17B10SMN1; SMN2 | |
| SCHEMBL15324749 | 0.71 | POLB (0.61) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL438267 | 0.71 | CCNB2 (0.39) | KDM4ETYMPSMN1; SMN2ALKBH3KMT2A | |
| SCHEMBL15285375 | 0.69 | CYP1A2 (0.49) | ALDH1A1KDM4ECYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6920607 | 0.69 | MAPT (0.61) | ALDH1A1KDM4ECYP3A4HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513277-B2 | Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2013-08-20 | — | — | US | disclosed |
| US-8148529-B2 | Pyrrolo[3,2-C] pyridine derivatives and processes for the preparation thereof | YUHAN CORPORATION (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20120065224-A1 | PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2012-03-15 | — | — | US | disclosed |
| EP-1784402-B1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2011-08-03 | — | — | EP | disclosed |
| US-20090005409-A1 | Pyrrolo[3,2-C] Pyrdine Derivatives and Processes for the Preparation Thereof | YUHAN CORPORATION (KR) | 2009-01-01 | — | — | US | disclosed |
| EP-1784402-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007001139-A1 | A COMPOSITION FOR TREATING OR PREVENTING A CANCER COMPRISING PYRROLOPYRIDINE DERIVATIVES | YUHAN CORPORATION (KR) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006025714-A1 | PYRROLO[3,2-c]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005409-A1 | Pyrrolo[3,2-C] Pyrdine Derivatives and Processes for the Preparation Thereof | ATP6AP1, PPOX, PGA5 | ALDH1A1 2372/4885KDM4E 1871/4885CYP1A2 247/4885 |
| US-20120065224-A1 | PYRROLO[3,2-C) PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | PGA5, ATP6AP1, HPD | ALDH1A1 2172/4885KDM4E 1016/4885CYP1A2 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.